FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer

November 6, 2017 – The U.S. Food and Drug Administration today expanded the approval of vemurafenib to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Vemurafenib is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD. “Today’s approval of Vemurafenib for patients with ECD demonstrates how we can apply … (leggi tutto)